Medicines adaptive pathways to patients: Why, when, and how to engage?
- Medicines Adaptive Pathways to Patients (MAPPs) seeks to foster access to novel beneficial treatments for the right patient groups at the earliest appropriate time in the product life‐span, in a sustainable fashion. We summarize the MAPPs engagement process and critical questions to be asked at each milestone of the product life‐span. These considerations are of relevance for regulatory and access pathways that strive to address the “evidence vs. access” conundrum.
- Publication status:
- Peer review status:
- Peer reviewed
- Pubs id:
- Local pid:
- Deposit date:
- Copyright holder:
- Eichler et al
- Copyright date:
Copyright © 2018 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
If you are the owner of this record, you can report an update to it here: Report update to this record